Similar articles

• Serological monitoring of protection of sheep against Echinococcus granulosus induced by the EG95 vaccine.

  Heath DD, Koolaard J. Heath DD, et al. Parasite Immunol. 2012 Jan;34(1):40-4. doi: 10.1111/j.1365-3024.2011.01341.x. Parasite Immunol. 2012. PMID: 22043983 Clinical Trial.
• Immunity and vaccine control of Echinococcus granulosus infection in animal intermediate hosts.

  Lightowlers MW, Heath DD. Lightowlers MW, et al. Parassitologia. 2004 Jun;46(1-2):27-31. Parassitologia. 2004. PMID: 15305682 Review.
• Antigenic differences between the EG95-related proteins from Echinococcus granulosus G1 and G6 genotypes: implications for vaccination.

  Alvarez Rojas CA, Gauci CG, Lightowlers MW. Alvarez Rojas CA, et al. Parasite Immunol. 2013 Feb;35(2):99-102. doi: 10.1111/pim.12009. Parasite Immunol. 2013. PMID: 23009356
• Efficacy of the EG95 hydatid vaccine in a macropodid host, the tammar wallaby.

  Barnes TS, Hinds LA, Jenkins DJ, Coleman GT, Colebrook AL, Kyngdon CT, Gauci CG, Lightowlers MW. Barnes TS, et al. Parasitology. 2009 Apr;136(4):461-8. doi: 10.1017/S0031182009005526. Epub 2009 Feb 6. Parasitology. 2009. PMID: 19195411 Clinical Trial.
• Hydatid disease: vaccinology and development of the EG95 recombinant vaccine.

  Gauci C, Heath D, Chow C, Lightowlers MW. Gauci C, et al. Expert Rev Vaccines. 2005 Feb;4(1):103-12. doi: 10.1586/14760584.4.1.103. Expert Rev Vaccines. 2005. PMID: 15757477 Review.